Alternative splicing in multiple sclerosis and other autoimmune diseases

RNA Biology

Volumn 7, Issue 4, 2010, Pages 462-473

  Evsyukova, Irina ^a   Somarelli, Jason A ^a   Gregory, Simon G ^a   Garcia Blanco, Mariano A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alternative splicing; Autoimmune disease; Interleukin 7 receptor alpha chain; Multiple sclerosis; SNP

Indexed keywords

CD45 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 7 RECEPTOR; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

ALLELE; ALTERNATIVE RNA SPLICING; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 GENE; DISEASE PREDISPOSITION; EXON; GENE; GENE EXPRESSION; HUMAN; INNER EAR DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; INTERLEUKIN 7 RECEPTOR GENE; KINESIN LIGHT CHAIN 1 GENE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NONHUMAN; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCERATIVE COLITIS;

METAZOA;

EID: 77957317868     PISSN: 15476286     EISSN: 15558584     Source Type: Journal    
DOI: 10.4161/rna.7.4.12301     Document Type: Review

References (130)

1. Tycowski KT, Kolev NG, Conrad NK, Fok V, Steitz JA. The ever-growing world of small nuclear ribonucleoproteins. In: Gesteland RF, Cech TR, Atkins JF, eds. The RNA World. Third edition. NY: CSHL Press 2006; 329-36.
2. Cooper TA, Wan L, Dreyfuss G. RNA and disease. Cell 2009; 136:777-93.
3. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, et al. Alternative isoform regulation in human tissue transcriptomes. Nature 2008; 456:470-6. (Pubitemid 352759009)
4. Wang G-S, Cooper TA. Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev 2007; 8:749-61.
5. Goldstrohm AC, Greenleaf AL, Garcia-Blanco MA. Co-transcriptional splicing of pre-messenger RNAs: considerations for the mechanism of alternative splicing. Gene 2001; 277:31-47.
6. Wahl MC, Will CL, Lührmann R. The spliceosome: design principles of a dynamic RNP machine. Cell 2009; 136:701-18.
7. Staley JP, Woolford JL Jr. Assembly of ribosomes and spliceosomes: complex ribonucleoprotein machines. Curr Opin Cell Biol 2009; 21:109-18.
8. Smith DJ, Query CC, Konarska MM. Nought may endure but mutability: spliceosome dynamics and the regulation of splicing. Mol Cell 2008; 30:657-66.
9. Jurica MS. Detailed close-ups and the big picture of spliceosomes. Curr Opin Struct Biol 2008; 18:315-20.
10. Patel AA, Steitz JA. Splicing double: insights from the second spliceosome. Nat Rev Mol Cell Biol 2003; 4:960-70.
11. Garcia-Blanco MA, Baraniak AP, Lasda EL. Alternative splicing in disease and therapy. Nat Biotechnol 2004; 22:535-46.
12. Carstens RP, McKeehan WL, Garcia-Blanco MA. An intronic sequence element mediates both activation and repression of rat fibroblast growth factor receptor 2 pre-mRNA splicing. Mol Cell Biol 1998; 18:2205-17.
13. Lynch KW. Consequences of regulated pre-mRNA splicing in the immune system. Nat Rev 2004; 4:931-40.
14. Grigoryev YA, Kurian SM, Nakorchevskiy AA, Burke JP, Campbell D, Head SR, et al. Genome-wide analysis of immune activation in human T and B cells reveals distinct classes of alternatively spliced genes. PLoS ONE 2009; 4:e7906.
15. Lopez-Bigas N, Audit B, Ouzounis C, Parra G, Guigó R. Are splicing mutations the most frequent cause of hereditary disease? FEBS Lett 2005; 579:1900-3.
16. Coyle PK. Multiple sclerosis. In: Lahita RG, ed. Textbook of the autoimmune diseases. Lippincott Williams & Wilkins 2000; 595-609.
17. Duquette P, Pleines J, Girard M, Charest L, Senecal-Quevillon M, Masse C. The increased susceptibility of women to multiple sclerosis. Can J Neurol Sci 1992; 19:466-71.
18. Mazzucchelli R, Durum SK. Interleukin-7 receptor expression: intelligent design. Nat Rev Immunol 2007; 7:144-53.
19. Gregory SG, Schmidt S, Seth P, Oksenberg JR, Hart J, Prokop A, et al. Interleukin 7 receptor á chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genetics 2007; 39:1083-91. (Pubitemid 47340652)
20. Lundmark F, Duvefelt K, Iacobaeus E, Kockum I, Wallström E, Khademi M, et al. Variation in interleukin 7 receptor á chain (IL7R) influences risk of multiple sclerosis. Nat Genetics 2007; 39:1108-13. (Pubitemid 47340654)
21. The International Multiple Sclerosis Genetics Consortium. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357:851-62.
22. Goodwin RG, Friend D, Ziegler SF, Jerzy R, Falk BA, Gimpel S, et al. Cloning of the human and murine interleukin-7 receptors: demonstration of a soluble form and homology to a new receptor superfamily. Cell 1990; 60:941-51. (Pubitemid 20103876)
23. Korte A, Köchling J, Badiali L, Eckert C, Andreae J, Geilen W, et al. Expression analysis and characterization of alternatively spliced transcripts of human IL7Rá chain encoding two truncated receptor proteins in relapsed childhood ALL. Cytokine 2000; 12:1597-608.
24. McKay FC, Swain LI, Schibeci SD, Rubio JP, Kilpatrick TJ, Heard RN, et al. Haplotypes of the interleukin7 receptor alpha gene are correlated with altered expression in whole blood cells in multiple sclerosis. Genes and Immunity 2008; 9:1-6.
25. Liu GZ, Fang LB, Hjelmstrom P, Gao XG. Increased CD8+ central memory T cells in patients with multiple sclerosis. Mult Scler 2007; 13:149-55. (Pubitemid 46592766)
26. + T-effector memory cells in peripheral blood of patients with relapsing-remitting multiple sclerosis compared to healthy controls. J Neuroimmunol 2007; 183:168-74.
27. Lunemann JD, Munz C. Epstein-Barr virus and multiple sclerosis. Curr Neurol Neurosci Rep 2007; 7:253-8.
28. Grigoriadis N, Hadjigeorgiuo GM. Virus-mediated autoimmunity in multiple sclerosis. J Autoimmune Dis 2006; 3:1-8.
29. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443:350-4. (Pubitemid 44435155)
30. Mueller SN, Ahmed R. High antigen levels are the cause of T cell exhaustion during chronic viral infection. PNAS 2009; 106:8623-8.
31. Ueda H, Howson JMM, Esposito L, Heward J, Snook H, Chamberlain G, et al. Association of the T-cell regulatory gene CTLA-4 with susceptibility to autoimmune disease. Nature 2003; 423:506-11. (Pubitemid 36648570)
32. Ligers A, Xu C, Saarinen S, Hillert J, Olerup O. The CTLA-4 gene is associated with multiple sclerosis. J Neuroimmunol 1999; 97:182-90. (Pubitemid 29301428)
33. Kristiansen OP, Larsen ZM, Pociot F. CTLA-4 in autoimmune diseases - a general susceptibility gene to autoimmunity? Genes and Immunity 2000; 1:170-84.
34. Ligers A, Teleshova N, Masterman T, Huang W-X, Hillert J. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes and Immunity 2001; 2:145-52. (Pubitemid 33674879)
35. Kantarci OH, Hebrink DD, Achenbach SJ, Atkinson EJ, Waliszewska A, Buckle G, et al. CTLA-4 is associated with susceptibility to multiple sclerosis. J Neuroimmunol 2003; 134:133-41. (Pubitemid 36050839)
36. Van Veen T, Crusius J, Bart A, van Winsen L, Xia B, Barkhof F, Salvador Pena A, et al. CTLA-4 and CD28 gene polymorphisms in susceptibility, clinical course and progression of multiple sclerosis. J Neuroimmunol 2003; 140:188-93. (Pubitemid 36836105)
37. Anjos SM, Shao W, Marchand L, Polychronakos C. Allelic effects on gene regulation at the autoimmunity-predisposing CTLA-4 locus: a re-evaluation of the 3′ + 6230G>A polymorphism. Genes and Immunity 2005; 6:305-11. (Pubitemid 40903403)
38. Roxburgh RH, Sawcer S, Maranian M, Seaman S, Hensiek A, Yeo T, et al. No evidence of a significant role for CTLA-4 in multiple sclerosis. J Neuroimmunol 2006; 171:193-7. (Pubitemid 41832291)
39. Bagos PG, Karnaouri AC, Nikolopoulos GK, Hamodrakas SJ. No evidence for association of CTLA-4 gene polymorphisms with the risk of developing multiple sclerosis: a meta-analysis. Multiple Sclerosis 2007; 13:156-68.
40. Palacios R, Comas D, Elorza J, Villoslada P. Genomic regulation of CTLA-4 and multiple sclerosis. J Neuroimmunol 2008; 203:108-15.
41. Karabon L, Kosmaczewska A, Bilinska M, Pawlak E, Ciszak L, Jedynak A, et al. The CTLA-4 gene polymorphisms are associated with CTLA-4 protein expression levels in multiple sclerosis patients and with susceptibility to disease. Immunology 2009; 128:787-96.
42. Carreno BM, Bennett F, Chau TA, Ling V, Luxenberg D, Jussif J, et al. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression. J Immunol 2000; 165:1352-6. (Pubitemid 30604565)
43. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995; 270:985-8.
44. Chen Z, Stockton J, Mathis D, Benoist C. Modeling CTLA-4-linked autoimmunity with RNA interference in mice. PNAS 2006; 103:16400-5. (Pubitemid 44715208)
45. Oaks MK, Hallett KM, Penwell RT, Stauber EC, Warren SJ, Tector AJ. A native soluble form of CTLA-4. Cell Immunol 2000; 201:144-53.
46. Pawlak E, Kochanowska IE, Frydecka I, Kielbinski M, Potoszek S, Bilinska M. The soluble CTLA-4 receptor: a new marker in autoimmune diseases. Arch Immunol Ther Exp 2005; 53:336-41. (Pubitemid 43186762)
47. Perkins D, Wang Z, Donovan C, He H, Mark D, Guan G, et al. Regulation of CTLA-4 expression during T cell activation. J Immunol 1996; 156:4154-9. (Pubitemid 26165810)
48. Magistrelli G, Jeannin P, Herbault N, Benoit de Coignac A, Gauchat JF, Bonnefoy JY, et al. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol 1999; 29:3596-602. (Pubitemid 29527807)
49. Gu M, Kakoulidou M, Giscombe R, Pirskanen R, Lefvert AK, Klareskog L, et al. Identification of CTLA- 4 isoforms produced by alternative splicing and their association with Myasthenia gravis. Clin Immunol 2008; 128:374-81.
50. + regulatory T cells. J Immunol 2009; 182:49-10.
51. Holmes N. A splicing switch for T cells. Science 2008; 321:646-7.
52. Hermiston ML, Xu Z, Weiss A. CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol 2003; 21:107-37.
53. Jacobsen M, Schweer D, Ziegler A, Gaber R, Schock S, Schwinzer R, et al. A point mutation in PTPRC is associated with the development of multiple sclerosis. Nat Genetics 2000; 26:495-8.
54. Jacobsen M, Hoffmann S, Cepok S, Stei S, Ziegler A, Sommer N, et al. A novel mutation in PTPRC interferes with splicing and alters the structure of the human CD45 molecule. Immunogenetics 2002; 54:158-63.
55. Boxall S, Stanton T, Hirai K, Ward V, Yasui T, Tahara H, et al. Disease associations and altered immune function in CD45 138G variant carriers. Hum Mol Gen 2004; 13:2377-84.
56. Ward V, Hennig BJ, Hirai K, Tahara H, Tamori A, Dawes R, et al. Geographical distribution and disease associations of the CD45 exon 6 138G variant. Immunogenetics 2006; 58:235-9.
57. Gomez-Lira M, Liguori M, Magnani C, Bonamini D, Salviati A, Leone M, et al. CD45 and multiple sclerosis: the exon 4 C77G polymorphism (additional studies and meta-analysis) and new markers. J Neuroimmunol 2003; 140:216-21.
58. Vorechovsky I, Kralovicova J, Tchilian E, Masterman T, Zhang Z, Ferry B, et al. Does 77C→G in PTPRC modify autoimmune disorders linked to the major histocompatibility complex? Nat Genetics 2001; 29:22-3.
59. Barcellos LF, Caillier S, Dragone L, Elder M, Vittinghoff E, Bucher P, et al. PTPRC (CD45) is not associated with the development of multiple sclerosis in US patients. Nat Genet 2001; 29:23-4.
60. Miterski B, Sindern E, Haupts M, Schimrigk S, Epplen JT. PTPRC (CD45) is not associated with multiple sclerosis in a large cohort of German patients. BMC Med Gen 2002; 3:1-3.
61. Cocco E, Murru MR, Melis C, Schirru L, Solla E, Lai M, et al. PTPRC (CD45) C77G mutation does not contribute to multiple sclerosis susceptibility in Sardinian patients. J Neurol 2004; 251:1085-8.
62. Tchilian EZ, Dawes R, Ramaley PA, Whitworth JA, Yuldasheva N, Spencer Wells R, et al. A CD45 polymorphism associated with abnormal splicing is absent in African populations. Immunogenetics 2002; 53:980-3. (Pubitemid 34211810)
63. Lynch KW, Weiss A. A CD45 polymorphism associated with multiple sclerosis disrupts an exonic splicing silencer. J Biol Chem 2001; 26:24341-7. (Pubitemid 37410844)
64. Topp JD, Jackson J, Melton AA, Lynch KW. A cell-based screen for splicing regulators identifies hnRNP LL as a distinct signal-induced repressor of CD45 variable exon 4. RNA 2008; 14:2038-49.
65. Oberdoerffer S, Ferreira Moita L, Neems D, Freitas RP, Hacohen N, Rao A. Regulation of CD45 alternative splicing by heterogeneous ribonucleoprotein, hnRN-PLL. Science 2008; 321:686-91.
66. Wu Z, Jia X, de la Cruz L, Su X-C, Marzolf B, Troisch P, et al. Memory T cell RNA rearrangement programmed by heterogeneous nuclear ribonucleoprotein hnRNPLL. Immunity 2008; 29:863-75.
67. Wang H-Y, Xu X, Ding J-H, Bermingham JR Jr, Fu X-D. SC35 plays a role in T cell development and alternative splicing of CD45. Mol Cell 2001; 7:331-42. (Pubitemid 32206501)
68. Fedetz M, Matesanz F, Caro-Maldonado A, Fernandez O, Tamayo JA, Guerrero M, et al. OAS1 gene haplotype confers susceptibility to multiple sclerosis. Tissue Antigens 2006; 68:446-9.
69. Bonnevie-Nielsen V, Leigh Field L, Lu S, Zheng D-J, Li M, Martensen PM, et al. Variation in antiviral 2′,5′-oligoadenylate synthetase (2′5′AS) enzyme activity is controlled by a single-nucleotide polymorphism at a splice-acceptor site in the OAS1 gene. Am J Hum Genet 2005; 76:623-33. (Pubitemid 40432169)
70. Leigh Field L, Bonnevie-Nielsen V, Pociot F, Lu S, Nielsen TB, Beck-Nielsen H. OAS1 splice site polymorphism controlling antiviral enzyme activity influences susceptibility to type 1 diabetes. Diabetes 2005; 54:1588-91.
71. Tessier M-C, Qu H-Q, Frechette R, Bacot F, Grabs R, Taback SP, et al. Type 1 diabetes and the OAS gene cluster: association with splicing polymorphism or haplotype? J Med Genet 2006; 43:129-32.
72. Smyth DJ, Cooper JD, Lowe CE, Nutland S, Walker NM, Clayton DG, et al. No evidence for association of OAS1 with type 1 diabetes in unaffected siblings or type 1 diabetic cases. Diabetes 2006; 55:1525-8. (Pubitemid 44195397)
73. Qu HQ, Polychronakos C, Type 1 Diabetes Genetics Consortium. Reassessment of the type 1 diabetes association of the OAS1 locus. Genes Immun 2009; 10:69-73.
74. Szolnoki Z, Kondacs A, Mandi Y, Somogyvari F. A cytoskeleton motor protein genetic variant may exert a protective effect on the occurrence of multiple sclerosis: the janus face of the kinesin light-chain 1 56836CC genetic variant. Neuromol Med 2007; 9:335-9. (Pubitemid 350242637)
75. Carson JH, Worboys K, Ainger K, Barbarese E. Translocation of myelin basic protein mRNA in oligodendrocytes requires microtubules and kinesin. Cell Motil Cytoskeleton 1997; 38:318-28. (Pubitemid 27521603)
76. McCart AE, Mahony D, Rothnagel JA. Alternatively spliced products of the human kinesin light chain 1 (KNS2) gene. Traffic 2003; 4:576-80. (Pubitemid 36896549)
77. Ng B, Yang F, Huston DP, Yan Y, Yang Y, et al. Increased noncanonical splicing of autoantigen transcripts provides the structural basis for expression of untolerized epitopes. J Allergy Clin Immunol 2004; 114:1463-70. (Pubitemid 39575906)
78. Yang D, Chen IH, Xiong Z, Yan Y, Wang H, Yang X-F. Model of stimulation-responsive splicing and strategies in identification of immunogenic isoforms of tumor antigens and autoantigens. Clin Immunol 2006; 121:121-33. (Pubitemid 44592577)
79. Shiryaev SA, Savinov AY, Cieplak P, Ratnikov BI, Motamedchaboki K, Smith JW, et al. Matrix metalloproteinase proteolysis of the myelin basic protein isoforms is a source of immunogenic peptides in autoimmune multiple sclerosis. PLoS ONE 2009; 4:4952.
80. Pribyl TM, Campagnoni CW, Kampf K, Kashima T, Handley VW, McMahon J, et al. The human myelin basic protein gene is included within a 179-kilobase transcription unit: expression in the immune and central nervous systems. PNAS 1993; 90:10695-9.
81. Pribyl TM, Campagnoni C, Kampf K, Handley VS, Campagnoni AT. The major myelin protein genes are expressed in the human thymus. J Neurosci Res 1996; 45:812-9.
82. Delarasse C, Della Gaspera B, Lu CW, Lachapelle F, Gelot A, Rodriguez D, et al. Complex alternative splicing of the myelin oligodendrocyte glycoprotein gene is unique to human and non-human primates. J Neurochem 2006; 98:1707-17.
83. Boyle LH, Traherne JA, Plotnek G, Ward R, Trowsdale J. Splice variation in the cytoplasmic domains of myelin oligodendrocyte glycoprotein affects its cellular localization and transport. J Neurochem 2007; 102:1853-62. (Pubitemid 47329279)
84. Allamargot C, Gardinier MV. Alternative isoforms of myelin/ oligodendrocyte glycoprotein with variable cytoplasmic domains are expressed in human brain. J Neurochem 2007; 101:298-312. (Pubitemid 46525266)
85. Pribyl TM, Campagnoni CW, Kampf K, Kashima T, Handley VW, McMahon J, Campagnoni AT. Expression of the myelin proteolipid protein gene in the human fetal thymus. J Neuroimmunol 1996; 67:125-30. (Pubitemid 26252871)
86. Wang E, Huang Z, Hobson GM, Dimova N, Sperle K, McCullough A, et al. PLP1 alternative splicing in differentiating oligodendrocytes: characterization of an exonic splicing enhancer. J Cell Biochem 2005; 97:999-1016.
87. Wang E, Dimova N, Cambi F. PLP/DM20 ratio is regulated by hnRNPH and F and a novel G-rich enhancer in oligodendrocytes. NAR 2007; 35:4164-78. (Pubitemid 47244636)
88. Wang E, Dimova N, Sperle K, Huang Z, Lock L, McCullough MC, et al. Deletion of a splicing enhancer disrupts PLP1/DM20 ratio and myelin stability. Exp Neurol 2008; 214:322-30.
89. Wang E, Cambi F. Heterogenous nuclear ribonucleoproteins H and F regulate the proteolipid protein/DM20 ratio by recruiting U1 small nuclear ribonucleoprotein through a complex array of G runs. J Biol Chem 2009; 284:11194-204.
90. Klein L, Klugmann M, Nave K-A, Tuohy VK, Kyewski B. Shaping of the autoreactive T-cell repertoire by a splice variant of self protein expressed in thymic epithelial cells. Nat Med 2000; 6:56-61. (Pubitemid 30048526)
91. Perron H, Lang A. The human endogenous retrovirus link between genes and environment in multiple sclerosis and in multifactorial diseases associating neuroinflammation. Clin Rev Allergy Immunol 2009; DOI 10.1007/s12016-009-8170-x.
92. Christensen T, Sorensen PD, Hansen HJ, Moller-Larsen A. Antibodies against a human endogenous retrovirus and the preponderance of env splice variants in multiple sclerosis patients. Mult Scler 2003; 9:6-15. (Pubitemid 36253689)
93. Blond J-L, Beseme F, Duret L, Bouton O, Bedin F, Perron H, et al. Molecular characterization and placental expression of HERV-W, a new human endogenous retrovirus family. J Virol 1999; 73:1175-85. (Pubitemid 29036769)
94. v dysmyelination by a single isoform of the selective RNA-binding protein QKI. J Neurosci 2006; 26:11278-86.
95. Ryder SP, Williamson JR. Specificity of the STAR/GSG domain protein Qk1: implications for the regulation of myelination. RNA 2004; 10:1449-58.
96. Wu JI, Reed RB, Grabowski PJ, Artzt K. Function of quaking in myelination: regulation of alternative splicing. PNAS 2002; 99:4233-8.
97. Rider LG, Targoff IN. Muscle diseases. In: Lahita RG, ed. Textbook of the autoimmune diseases. Lippincott Williams & Wilkins 2000; 462-7.
98. Brenner T, Hamra-Amitay J, Evron T, Boneva N, Seidman S, Soreq H. The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis. FASEB J 2003; 17:214-22. (Pubitemid 36164391)
99. Sussman JD, Argov Z, McKee D, Hazum E, Brawer S, Soreq H. Antisense treatment for Myasthenia gravis. Experience with Monarsen. Ann NY Acad Sci 2008; 1132:283-90.
100. Gu M, Kakoulidou M, Giscombe R, Pirskanen R, Lefvert AK, Klareskog L, et al. Identification of CTLA-4 isoforms produced by alternative splicing and their association with myasthenia gravis. Clinical Immunol 2008; 128:374-81.
101. Muise AM, Walters T, Wine E, Griffiths AM, Turner D, Duerr RH, et al. Protein-tyrosine phosphatase sigma is associated with ulcerative colitis. Curr Biol 2007; 17:1212-8. (Pubitemid 47049795)
102. Onouchi Y, Gunji T, Burns JC, Shimizu C, Newburger JW, Yashiro M, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet 2008; 40:35-42.
103. Xiao X, Wang Z, Jang M, Nutiu R, Wang ET, Burge CB. Splice site strength-dependent activity and genetic buffering by poly-G runs. Nat Struct Mol Biol 2009; 16:1094-100.
104. Lahita RG. Systemic Lupus Erythematosus. In: Lahita RG, ed. Textbook of the autoimmune diseases. Lippincott Williams & Wilkins 2000; 537-47.
105. Sestak AL, Nath SK, Sawalha AH, Harley JB. Current status of lupus genetics. Arthritis Res Ther 2007; 9:210.
106. Kozyrev SV, Abelson A-K, Wojcik J, Zaghlool A, Prasad Linga Reddy MV, Sanchez E, et al. Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat Genet 2008; 40:211-6.
107. Mamegano K, Kuroki K, Miyashita R, Kusaoi M, Kobayashi S, Matsuta K, et al. Association of LILRA2 (ILT1, LIR7) splice site polymorphism with systemic lupus erythematosus and microscopic polyangiitis. Genes and Immunity 2008; 9:214-23.
108. Tsuzaka K, Setoyama Y, Yoshimoto K, Shiraishi K, Suzuki K, Abe T, et al. A splice variant of the TCRζ mRNA lacking exon 7 leads to the downregulation of TCRζ, the TCR/CD3 complex, and IL-2 production in systemic lupus erythematosus T cells. J Immunol 2005; 174:3518-25. (Pubitemid 40354060)
109. Tsuzaka K, Fukuhara I, Setoyama Y, Yoshimoto K, Suzuki K, Abe T, et al. TCRζ mRNA with an alternatively spliced 3′-untranslated region detected in systemic lupus erythematosus patients leads to the downregulation of TCRζ and TCR/CD3 complex. J Immunol 2003; 171:2496-503. (Pubitemid 37025558)
110. Tsuzaka K, Nozaki K, Kumazawa C, Shiraishi K, Setoyama Y, Yoshimoto K, et al. TCRζ mRNA splice variant forms observed in the peripheral blood T cells from systemic lupus erythematosus patients. Springer Semin Immun 2006; 28:185-93. (Pubitemid 46628483)
111. Rose-John S, Waetzig GH, Scheller J, Grotzinger J, Seegert D. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets 2007; 11:613-24. (Pubitemid 46730080)
112. Kotake S, Sato K, Kim KJ, Takajashi N, Udagawa N, Nakamura I, et al. Interleukin-6 and soluble interleukin- 6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996; 11:88-95. (Pubitemid 26026748)
113. Lainez B, Fernandez-Reeal JM, Romero X, Esplugues E, Canete JD, Ricart W, et al. Identification and characterization of a novel spliced variant that encodes human soluble tumor necrosis factor receptor 2. Int Immunol 2004; 16:169-77. (Pubitemid 38054638)
114. Graham RR, Kozyrev SV, Baechler EC, Prasad Linga Reddy MV, Plenge RM, Bauer JW, et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006; 38:550-5.
115. Yasuda S, Stevens RL, Terada T, Takeda M, Hashimoto T, Fukae J, et al. Defective expression of Ras Guanyl Nucleotide-Releasing protein 1 in a subset of patients with systemic lupus erythematosus. J Immunol 2007; 179:4890-900.
116. Hitomi Y, Tsuchiya N, Kawasaki A, Ohashi J, Suzuki T, Kyogoku X, et al. CD72 polymorphisms associated with alternative splicing modify susceptibility to human systemic lupus erythematosus through epistatic interaction with FCGR2B. Hum Mol Gen 2004; 13:2907-17. (Pubitemid 39585223)
117. Wei C-C, Chang M-S. A novel transcript of mouse interleukin-20 receptor acts on glomerular mesangial cells as an aggravating factor in lupus nephritis. Genes and Immunity 2008; 9:668-79.
118. Douglas KB, Windels DC, Zhao, Gadeliya AV, Wu H, Kaufmann KM, et al. Complement receptor 2 polymorphisms associated with systemic lupus erythematosus modulate alternative splicing. Genes Immun 2009; 10:457-69.
119. Sakkas LI, Tourtellotte C, Berney S, Myers AR, Platsoucas CD. Increased levels of alternatively spliced interleukin 4 (IL-4δ2) transcripts in peripheral blood mononuclear cells from patients with systemic sclerosis. Clin Diagn Lab Immunol 1999; 6:660-4. (Pubitemid 29441169)
120. Atamas SP, White B. Interleukin 4 in systemic sclerosis: not just an increase. Clin Diagn Lab Immunol 1999; 6:658-9. (Pubitemid 29441168)
121. Hasegawa M, Nakoshi Y, Muraki M, Sudo A, Kinoshita N, Yoshida T, et al. Expression of large tenascin-C splice variants in synovial fluid of patients with rheumatoid arthritis. J Orthop Res 2007; 25:563-8. (Pubitemid 46730509)
122. Kojo S, Tsutsumi A, Goto D, Sumida T. Low expression levels of soluble CD1d gene in patients with rheumatoid arthritis. J Rheumatol 2003; 30:2524-8. (Pubitemid 37549324)
123. Croft DR, Dall P, Davies D, Jackson DG, McIntyre P, Kramer IM. Complex CD44 splicing combinations in synovial fibroblasts from arthritic joints. Eur J Immunol 1997; 27:1680-4. (Pubitemid 27302849)
124. Wibulswas A, Croft D, Pitsillides AA, Bacarese- Hamilton I, McIntyre P, Genot E, et al. Influence of epitopes CD44v3 and CD44c6 in the invasive behavior of fibroblast-like synoviocytes derived from rheumatoid arthritis joints. Arthritis & Rheumatism 2002; 46:2059-64.
125. Naor D, Nedvetzki S. CD44 in rheumatoid arthritis. Arthritis Res Ther 2003; 5:105-15.
126. Shiozawa K, Hino K, Shiozawa S. Alternatively spliced EDA-containing fibronectin in synovial fluid as a predictor of rheumatoid joint destruction. Rheumatology 2001; 40:739-42. (Pubitemid 32707773)
127. Michel J, Langstein J, Hofstadter F, Schwarz H. A soluble form of CD137 (ILA/4-1BB), a member of the TNF receptor family, is released by activated lymphocytes and is detectable in sera of patients with rheumatoid arthritis. Eur J Immunol 1998; 28:290-5.
128. Vambutas A, DeVoti J, Goldofsky E, Gordon M, Lesser M, Bonagura V. Alternate splicing of interleukin-1 receptor type II (IL1R2) in vitro correlates with clinical glucocorticoid responsiveness in patients with AIED. PLoS ONE 2009; 4:5293.
129. Qu H-Q, Lu Y, Marchand L, Bacot F, Frechette R, Tessier M-C, et al. Genetic control of alternative splicing in the TAP2 gene: Possible implication in the genetics of type 1 diabetes. Diabetes 2007; 56:270-5.
130. Diez J, Park Y, Zeller M, Brown D, Garza D, Ricordi C, et al. Differential splicing of the IA-2 mRNA in pancreas and lymphoid organs as a permissive genetic mechanism for autoimmunity against the IA-2 type 1 diabetes autoantigen. Diabetes 2001; 50:895-900.